Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Viscum album Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse

Alessandra Longhi, Marilena Cesari, Massimo Serra, Erminia Mariani, Alessandra Longhi, Marilena Cesari, Massimo Serra, Erminia Mariani

Abstract

Background: In relapsed osteosarcoma, the 5-yr postrelapse disease-free survival (PRDFS) rate after the second relapse is <20%. In June 2007, a randomized study was started comparing oral etoposide vs Viscum album fermentatum Pini (an extract derived from the parasitic plant Viscum album L., European mistletoe) as maintenance therapy in patients with metastatic osteosarcoma in complete surgical remission after the second relapse. The primary endpoint was the PRDFS rate at 12 months (compared to the historical control rate). This is a long-term updated result. Patients and Methods. 10 patients received oral etoposide 50 mg/m2 daily for 21 days every 28 days for 6 months, and 9 patients received Viscum album fermentatum Pini 3 times/wk subcutaneously for 1 year. The study closed early in July 2011 due to insufficient recruitment. Lymphocyte subpopulations were analyzed at T0, T3, T6, T9, and T12 months.

Results: On 30 June 2019, at a median follow-up ITT of 83 months (range 3-144 ms), a median PRDFS of 106 ms (2-144) was observed in the Viscum arm with 5/9 patients who never relapse vs a PRDFS of 7 months (3-134) in the etoposide arm (all patients in the Etoposide arm relapsed) (hazard ratio HR = 0.287, 95% CI: 0.076-0.884, p=0.03). Model forecast 10-yr overall survival rates as 64% in the Viscum arm and 33% in the etoposide arm. Lymphocyte subpopulation counts (CD3, CD4, and CD56) showed an increase in the Viscum arm while a decrease was observed in the etoposide arm during treatment.

Conclusions: After 12 years from the start of the trial, the patients in the Viscum arm continue to show a considerably longer PRDFS compared to oral etoposide, and a trend for an advantage in OS is evident even if the number of treated patients is too small to draw conclusions. Viscum as maintenance treatment after complete surgical remission in relapsed osteosarcoma should be further investigated and compared with other drugs.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Copyright © 2020 Alessandra Longhi et al.

Figures

Figure 1
Figure 1
Postrelapse disease-free survival.
Figure 2
Figure 2
Overall survival.
Figure 3
Figure 3
Total Lymphocyte count in Viscum- and Etoposide-treated patients at T0, T3, T6, T9, and T12.
Figure 4
Figure 4
Lymphocyte subgroup count in (a) Viscum and (b) etoposide.

References

    1. Bacci G., Briccoli A., Longhi A., et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncologica. 2005;44(7):748–755. doi: 10.1080/02841860500327503.
    1. Bielack S. S., Kempf-Bielack B., Branscheid D., et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive Cooperative Osteosarcoma Study Group patients. Journal of Clinical Oncology. 2009;27(4):557–565. doi: 10.1200/jco.2008.16.2305.
    1. Briccoli A., Rocca M., Salone M., Guzzardella G. A., Balladelli A., Bacci G. High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005. Surgical Oncology. 2010;19(4):193–199. doi: 10.1016/j.suronc.2009.05.002.
    1. Tirtei E., Asaftei S. D., Manicone R., et al. Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. Tumori Journal. 2018;104(3):202–206. doi: 10.1177/0300891617753257.
    1. Steinborn C., Klemd A. M., Sanchez-Campillo A.-S., et al. Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model. PLoS One. 2017;12(7) doi: 10.1371/journal.pone.0181553.e0181553
    1. Webster R. M. The immune checkpoint inhibitors: where are we now? Nature Reviews Drug Discovery. 2014;13(12):883–884. doi: 10.1038/nrd4476.
    1. Coley W. B. Contribution to the knowledge of sarcoma. Annals of Surgery. 1891;14:199–222. doi: 10.1097/00000658-189112000-00015.
    1. Miwa S., Shirai T., Yamamoto N., et al. Current and emerging targets in immunotherapy for osteosarcoma. Journal of Oncology. 2019;2019:8. doi: 10.1155/2019/7035045.7035045
    1. Bielack S. S., Smeland S., Whelan J. S., et al. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. Journal of Clinical Oncology. 2015;33(20):2279–2287. doi: 10.1200/jco.2014.60.0734.
    1. Meyers P. A., Schwartz C. L., Krailo M. D., et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-A report from the children’s oncology group. Journal of Clinical Oncology. 2008;26(4):633–638. doi: 10.1200/jco.2008.14.0095.
    1. Boye K., Longhi A., Næss S., et al. Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label phase 2 trial. CTOS. 20193224408
    1. Molassiotis A., Fernadez-Ortega P., Pud D., et al. Use of complementary and alternative medicine in cancer patients: a European survey. Annals of Oncology. 2005;16(4):655–663. doi: 10.1093/annonc/mdi110.
    1. Schwabe U., Paffrath D. Arzneiverordnungsreport 2005. Heidelberg, Germany: Springer-Verlag; 2005.
    1. Singh B. N., Saha C., Galun D., Upreti D. K., Bayry J., Kaveri S. V. European Viscum album: a potent phytotherapeutic agent with multifarious phytochemicals, pharmacological properties and clinical evidence. RSC Advances. 2016;6(28):23837–23857. doi: 10.1039/c5ra27381a.
    1. Elluru S. R., Van Huyen J. P., Delignat S., et al. Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity. Anticancer. 2009;29(8):2945–2950.
    1. Kleinsimon S., Kauczor G., Jaeger S., Eggert A., Seifert G., Delebinski C. ViscumTT induces apoptosis and alters IAP expression in osteosarcoma in vitro and has synergistic action when combined with different chemotherapeutic drugs. BMC Complementary and Alternative Medicine. 2017;17(1):p. 26. doi: 10.1186/s12906-016-1545-7.
    1. Twardziok M., Kleinsimon S., Rolff J., et al. Multiple active compounds from Viscum album L. synergistically converge to promote apoptosis in Ewing sarcoma. PLoS One. 2016;11(9) doi: 10.1371/journal.pone.0159749.e0159749
    1. Menke K., Schwermer M., Schramm A., Zuzak T. J. Preclinical evaluation of antitumoral and cytotoxic properties of viscum album fraxini extract on pediatric tumor cells. Planta Medica. 2019;85(14-15):1150–1159. doi: 10.1055/a-1013-0382.
    1. Saha C., Das M., Stephen-Victor E., Friboulet A., Bayry J., Kaveri S. V. Differential effects of viscum album preparations on the maturation and activation of human dendritic cells and CD4⁺ T cell responses. Molecules. 2016;21(7):p. 912. doi: 10.3390/molecules21070912.
    1. Domont J., Dumont S., Rahal A. S., et al. Metronomic chemotherapy using oral etoposide in metastatic osteosarcoma. Journal of Clinical Oncology. 2016;34 doi: 10.1200/jco.2016.34.15_suppl.e22504.e22504
    1. Le Deley M.-C., Leblanc T., Shamsaldin A., et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the société française d’Oncologie pédiatrique. Journal of Clinical Oncology. 2003;21(6):1074–1081. doi: 10.1200/jco.2003.04.100.
    1. Yagita M., Ieki Y., Onishi R., et al. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer. International Journal of Oncology. 1998;13(13):91–96. doi: 10.3892/ijo.13.1.91.
    1. Kikuta T., Shimazaki C., Hirai H., et al. Three cases of secondary acute myeloid leukemia after long-term treatment with oral etoposide. Rinsho Ketsueki. 1996;37(11):1276–1282.
    1. Ng A., Taylor G. M., Eden O. B. Secondary leukemia IN a child with neuroblastoma while ON oral etoposide: what is the Cause? Pediatric Hematology and Oncology. 2000;17(3):273–279. doi: 10.1080/088800100276460.
    1. Longhi A., Reif M., Mariani E., Ferrari S. A randomized study on postrelapse disease-free survival with adjuvant mistletoe versus oral etoposide in osteosarcoma patients. Evidence-Based Complementary and Alternative Medicine. 2014;2014:9. doi: 10.1155/2014/210198.210198
    1. Serra M., Scotlandi K., Reverter-Branchat G., et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. Journal of Clinical Oncology. 2003;21(3):536–542. doi: 10.1200/jco.2003.03.144.
    1. Senerchia A. A., Macedo C. R., Ferman S., et al. Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: a report from the Latin American Group of Osteosarcoma Treatment. Cancer. 2017;123(6):1003–1010. doi: 10.1002/cncr.30411.
    1. Ostermann T., Raak C., Büssing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer. 2009;9:p. 451. doi: 10.1186/1471-2407-9-451.
    1. Schöffski P., Riggert S., Fumoleau P., et al. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European organization for research and treatment of cancer new drug development group. Annals of Oncology. 2004;15(12):1816–1824. doi: 10.1093/annonc/mdh469.
    1. Steele M. L., Axtner J., Happe A., Kröz M., Matthes H., Schad F. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology. Integrative Cancer Therapies. 2015;14(2):140–148. doi: 10.1177/1534735414563977.
    1. Zuzak T. J., Wasmuth A., Bernitzki S., Schwermer M., Längler A. Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: a case series. Complementary Therapies in Medicine. 2018;40:198–202. doi: 10.1016/j.ctim.2018.01.002.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj